In January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is expected to be marketed under the tradename Fablyn.
In January 2008, Ligand Pharmaceuticals, in collaboration with Pfizer as its marketing partner, submitted a New Drug Application for lasofoxifene, which will likely be marketed under the trade name Fablyn.